Biopharma boosts MILabs’ growth to record levels

September 16, 2020

Biopharma boosts MILabs’ growth to record levels

MILabs’ translational imaging success is attracting more and more attention of the biopharma industry and biotech start-ups who are acquiring MILabs preclinical imaging equipment in great numbers to accelerate translation of their bench research to clinical applications. This contributes to a continues exponential growth of MILabs, mainly driven by the unique capabilities of MILabs’ in-vivo imaging platform, including the seamless integration of optical, X-ray CT, and nuclear tomography as well as ultra-high definition targeted radiotherapy imaging.

No longer lost in translation?

MILabs’ multi-modal imaging platform has been developed to assist “translation” of basic scientific findings in a laboratory setting into human applications. High-performance single modality in-vivo imaging modules can be upgraded at any time from e.g. ultra-high resolution and dose efficient CT units to deep tissue 3D optical units, and further to seamlessly integrated optical-nuclear configurations. This enables to close gaps between optical in-vitro benchwork to optical and nuclear in-vivo applications. Exclusive new modality configurations enable concurrent SPECT/PET imaging for a further one-to-one translation from SPECT to PET imaging for clinical applications, all at industry-leading image resolutions. Moreover, many research institutions and biopharma companies can now benefit from the high-resolution theranostics imaging capabilities, including any Alpha or Beta targeted radiotherapy.

Webinars: with a little help from our many friends

MILabs has a large base of installed modalities (over 250) at renowned academic institutions. Every week, new applications are being developed to harness knowledge from basic scientific research into preclinical research to create novel diagnostics and treatments. Hundreds of such applications have been documented in peer-reviewed scientific articles. Nevertheless, the translation of research findings to clinical applications remains a challenge. To further narrow the translational gap and promote a collaborative partnership model between academic research and the biopharma industry, MILabs has engaged a number of experts to conduct a series of on-demand webinars. During these seminars, the synergistic multimodal capabilities of MILabs’ upgradable, in-line in-vivo imaging systems will be highlighted. You can find the webinars by clicking on the image below: